The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.
about
Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional considerationGenomic approaches to identifying targets for treating β hemoglobinopathiesTissue factor and thrombin in sickle cell anemiaA systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis.Monomethylfumarate induces γ-globin expression and fetal hemoglobin production in cultured human retinal pigment epithelial (RPE) and erythroid cells, and in intact retina.MSC therapy attenuates obliterative bronchiolitis after murine bone marrow transplantRegulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancerMechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S.The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.Fetal hemoglobin in sickle cell anemiaPlatelet-neutrophil interactions under thromboinflammatory conditionsOsteoarticular involvement in sickle cell disease.Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease.Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.Myocardial infarction in sickle cell disease: use of translational imaging to diagnose an under-recognized problemVaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.Novel therapies targeting the endothelium in sickle cell disease.Interplay between coagulation and vascular inflammation in sickle cell disease.Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis.Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders.Emerging drugs for sickle cell anemia.Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells.Prothrombotic aspects of sickle cell disease.Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches.A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.Pathophisiology of sickle cell disease and new drugs for the treatment.Histone deacetylase inhibitor treatment attenuates coagulation imbalance in a lethal murine model of sepsisTherapeutic advances in sickle cell disease in the last decade.A monocyte-TNF-endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade.Modulating the expression of Chtop, a versatile regulator of gene-specific transcription and mRNA export.Erythrocytes and Vascular Function: Oxygen and Nitric Oxide.The Anti-inflammatory Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor α-Stimulated Endothelial Cells via Activation of GPR41/43 and Inhibition of HDACs.
P2860
Q26742061-CF2B5CD4-1E16-4659-8683-3B88FCB9E1B5Q26799214-BFA742FE-74B8-46A3-8A00-47253E91206DQ27024887-A0E727B1-0E12-43B5-BFDF-AD6843519CC4Q34038874-591D4BC9-AB15-4252-A9E7-B06D63149556Q34107594-89308E5C-CCC1-4918-B904-27AED4658FA4Q34278561-23C770C6-0792-421C-B5AE-63612CC8E214Q34420590-C9D96C21-DB87-4582-A328-B7046D749D15Q34924453-AD60F824-BFD5-43C4-AABD-9E541D70A9B9Q35052701-F9F96749-A6F2-4927-A9AD-AC0773DE8506Q35114500-A0B23272-9AF4-4DB0-A1A8-1FB28ADEAE71Q35779411-82003B34-D388-4ABC-9CBC-2C72D380B791Q36283152-77DEFC94-5886-4D9C-BA56-D2D63323B9DAQ36534381-DE42729E-C874-4836-96D6-CE5C19BA0D77Q36596850-0B9B499A-FA07-46C8-980A-2969253EE223Q36596855-22B01B12-BCDD-4B73-8B25-109C7FD853ACQ36673817-BF634B3C-581E-46C6-AFB4-D669503A95B8Q37370659-58CC2F11-C41B-4057-9609-E78FC9A7950AQ37489028-93F5E9A0-1B8E-4D1B-8D51-F9EA480A21C6Q37828315-9DD45176-2751-4E07-A577-C945566F8294Q37930655-77D93F46-8ECF-463F-ACE4-482E1678183BQ38099667-0B3E1E9A-0FFB-4DC3-9C85-E6DD659ED5DFQ38115527-1C814A96-A205-4FC3-A4E2-39D5A41E8F3DQ38186032-2DC6D94C-78C0-42EC-9746-C15684759F10Q38272226-1016E968-5FF5-45EE-BB41-0CE20B37804FQ38323856-373CED17-4B31-49C7-ACB7-0FFAA0D66244Q38696998-4FEBCCD8-E9ED-4F08-94DE-AB1127241E9AQ38995849-D8803344-BD63-4431-87BA-7D2C59D6AF64Q39390596-E245ECA3-43E0-417B-8BD9-A77248AA433AQ41777376-5706407B-8C0A-4748-8C15-94696F518FB1Q42681372-1E32108F-9B3D-42FC-A1A5-1E4E40589A33Q44223235-3E4D4138-A5D1-4BE7-A25D-1F87DBCFB598Q46081377-2B6D21A0-C7C7-4134-90F3-7F118DD34276Q52312877-168547EE-BFDA-427A-A8F2-54EF5EB920D7Q52665629-99500AD1-E767-40E8-9A92-B36D7DCE7670Q55347800-E6DB5A04-9A0E-497C-B443-6FA1C781F79E
P2860
The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The HDAC inhibitors trichostat ...... ogy of sickle transgenic mice.
@ast
The HDAC inhibitors trichostat ...... ogy of sickle transgenic mice.
@en
type
label
The HDAC inhibitors trichostat ...... ogy of sickle transgenic mice.
@ast
The HDAC inhibitors trichostat ...... ogy of sickle transgenic mice.
@en
prefLabel
The HDAC inhibitors trichostat ...... ogy of sickle transgenic mice.
@ast
The HDAC inhibitors trichostat ...... ogy of sickle transgenic mice.
@en
P2093
P2860
P1433
P1476
The HDAC inhibitors trichostat ...... ogy of sickle transgenic mice.
@en
P2093
Anna N Solovey
Arne Slungaard
Chine F Abanonu
Fuad Abdulla
Gregory M Vercellotti
John D Belcher
John W Eaton
Julia Nguyen
Julie V Vineyard
Rahn Kollander
P2860
P304
P356
10.1182/BLOOD-2009-02-204990
P407
P50
P577
2010-01-06T00:00:00Z